Mirvetuximab soravtansine
Checked 2026-09-09
Folate receptor alpha-high platinum-resistant ovarian cancer, 1-3 prior lines
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
| 6 mg/kg adjusted ideal body weight | IV | D1 |
Cycles
until progression
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- Ocular toxicity: baseline and periodic eye examination, steroid and lubricating eye drops.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days
BEP
Metastatic germ cell tumour: 3 cycles good risk, 4 cycles intermediate or poor risk
every 21 days × 3
Carboplatin + paclitaxel
Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC
every 21 days × 6
Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance
Stage III-IV ovarian cancer, especially with residual disease or ascites
every 21 days × 6
Weekly paclitaxel
Platinum-resistant ovarian cancer (with or without bevacizumab); metastatic breast cancer
every 28 days
Pegylated liposomal doxorubicin
Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma
every 28 days
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2
Niraparib maintenance
Newly diagnosed advanced ovarian cancer after platinum response, regardless of BRCA status
every 28 days × 3